Bibliography
- Matschinsky FM. GKAs for diabetes therapy: why no clinically useful drug after two decades of trying? Trends Pharmacol Sci 2013;34:90-9
- Filipski KJ, Pfefferkorn JA. A patent review of glucokinase activators and disruptors of the glucokinase - glucokinase regulatory protein interaction: 2011 - 2014. Expert Opin Ther Pat 2014;24(8):875-91
- Agius L. Glucokinase and molecular aspects of liver glycogen metabolism. Biochem J 2008;414:1-18
- Van Schaftingen E, Veiga-da-Cunha M, Niculescu L. The regulatory protein of glucokinase. Biochem Soc Trans 1997;25:136-40
- Meininger GE, Scott R, Alba M, et al. Effects of MK-0941, a novel glucokinase activator, on glycemic control in insulin-treated patients with type 2 diabetes. Diabetes Care 2011;34:2560-6
- Wilding JP, Leonsson-Zachrisson M, Wessman C, Johnsson E. Dose-ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin. Diabetes Obes Metab 2013;15:750-9
- Erion DM, Lapworth A, Amor PA, et al. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats. PLoS One 2014;9:e97139
- Lloyd DJ, St Jean DJ Jr, Kurzeja RJ, et al. Antidiabetic effects of glucokinase regulatory protein small-molecule disruptors. Nature 2013;504:437-40
- Baker DJ, Wilkinson GP, Atkinson AM, et al. Chronic glucokinase activator treatment at clinically translatable exposures gives durable glucose lowering in two animal models of type 2 diabetes. Br J Pharmacol 2014;171:1642-54
- Eiki J, Nagata Y, Futamura M, et al. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs. Mol Pharmacol 2011;80:1156-65
- De Ceuninck F, Kargar C, Ilic C, et al. Small molecule glucokinase activators disturb lipid homeostasis and induce fatty liver in rodents: a warning for therapeutic applications in humans. Br J Pharmacol 2013;168:339-53
- Waring MJ, Brogan IJ, Coghlan MJ, Johnstone C. Overcoming retionoic acid receptor alpha based testicular toxicity in the optimisation of glucokinase activators. MedChemComm 2011;2:771-3
- Ginsberg H, Olefsky JM, Kimmerling G, et al. Induction of hypertriglyceridemia by a low-fat diet. J Clin Endocrinol Metab 1976;42:729-35
- Arden C, Petrie JL, Tudhope SJ, et al. Elevated glucose represses liver glucokinase and induces its regulatory protein to safeguard hepatic phosphate homeostasis. Diabetes 2011;60:3110-20
- Arden C, Tudhope SJ, Petrie JL, et al. Fructose 2,6-bisphosphate is essential for glucose-regulated gene transcription of glucose-6-phosphatase and other ChREBP target genes in hepatocytes. Biochem J 2012;443:111-23
- Towle HC. Glucose as a regulator of eukaryotic gene transcription. Trends Endocrinol Metab 2005;16:489-94
- Agius L. High-carbohydrate diets induce hepatic insulin resistance to protect the liver from substrate overload. Biochem Pharmacol 2013;85:306-12
- Payne VA, Arden C, Lange AJ, Agius L. Contributions of glucokinase and phosphofructokinase-2/fructose bisphosphatase-2 to the elevated glycolysis in hepatocytes from Zucker fa/fa rats. Am J Physiol Regul Integr Comp Physiol 2007;293:R618-25
- Nakamura A, Shimazaki H, Ohyama S, et al. Effect of long-term treatment with a small-molecule glucokinase activator on glucose metabolism,lipid profiles and hepatic function. J Diabetes Investig 2011;2:276-9
- Winzell MS, Coghlan M, Leighton B, et al. Chronic glucokinase activation reduces glycaemia and improves glucose tolerance in high-fat diet fed mice. Eur J Pharmacol 2011;663:80-6